Kineta Total Current Assets 2014-2024 | KANT
Kineta total current assets from 2014 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Kineta Annual Total Current Assets (Millions of US $) |
2023 |
$6 |
2022 |
$14 |
2021 |
$11 |
2020 |
$88 |
2019 |
$16 |
2018 |
$121 |
2017 |
$76 |
2016 |
$90 |
2015 |
$15 |
2014 |
$11 |
2013 |
$6 |
Kineta Quarterly Total Current Assets (Millions of US $) |
2024-06-30 |
$1 |
2024-03-31 |
$2 |
2023-12-31 |
$6 |
2023-09-30 |
$8 |
2023-06-30 |
$13 |
2023-03-31 |
$10 |
2022-12-31 |
$14 |
2022-09-30 |
$9 |
2022-06-30 |
$15 |
2022-03-31 |
$20 |
2021-12-31 |
$11 |
2021-09-30 |
$48 |
2021-06-30 |
$58 |
2021-03-31 |
$67 |
2020-12-31 |
$88 |
2020-09-30 |
$42 |
2020-06-30 |
$51 |
2020-03-31 |
$60 |
2019-12-31 |
$16 |
2019-09-30 |
$80 |
2019-06-30 |
$91 |
2019-03-31 |
$108 |
2018-12-31 |
$121 |
2018-09-30 |
$48 |
2018-06-30 |
$63 |
2018-03-31 |
$66 |
2017-12-31 |
$76 |
2017-09-30 |
$46 |
2017-06-30 |
$61 |
2017-03-31 |
$75 |
2016-12-31 |
$90 |
2016-09-30 |
$103 |
2016-06-30 |
$44 |
2016-03-31 |
$51 |
2015-12-31 |
$15 |
2015-09-30 |
|
2015-06-30 |
|
2015-03-31 |
|
2014-12-31 |
$11 |
2013-12-31 |
$6 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|